Evaluation of Autologous Engineered Skin Substitute (ESS-W) Compared to Meshed, Split-Thickness Autograft (AG) for Treatment of Deep Partial- and Full-Thickness Thermal Burn Wounds in Adult Patients

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds.
The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Start Date01 Sep 2016

Sponsor / Collaborator

Amarantus Bioscience Holdings, Inc.

[+1]

100 Clinical Results associated with Engineered skin substitute(Lonza Group AG)

100 Translational Medicine associated with Engineered skin substitute(Lonza Group AG)

100 Patents (Medical) associated with Engineered skin substitute(Lonza Group AG)

Literatures (Medical) associated with Engineered skin substitute(Lonza Group AG)

01 Oct 2024·American Journal of Human Biology

Protective effects of diversified diets for dietary folate adequacy and serum homocysteine in breastfeeding mothers amid historic drought

Article

Author: Fujita, Masako ; Asthana, Ananyaa ; Wamwere‐Njoroge, George

AbstractObjectivesThe United Nations recommends that women consume ≥5 food groups, also known as the minimum dietary diversity score for women (MDD‐W), for nutritional health. This is increasingly unattainable for populations in climate hot zones coping with food insecurity by prioritizing calories over dietary breadth. Breastfeeding mothers may be particularly vulnerable to adverse health impacts of low dietary diversity due to elevated nutritional requirements for lactation. We investigated how the protective effects of MDD‐W for folate adequacy varies by MDD‐W score and mother–infant life history characteristics.MethodsWe conducted a secondary analysis of cross‐sectional data from breastfeeding mothers (n = 228) in northern Kenya, surveyed during the 2006 Horn‐of‐Africa drought. Logistic regression models for adequate dietary folate (and vitamins B12 and B6) and normal homocysteine (folate‐replete status) evaluated the effect of MDD‐W alone and in interaction with infant/maternal characteristics.ResultsMDD‐W (as ordinal or dichotomous variable) was positively associated with adequate folate (and vitamin B12). Having male infant was inversely associated with adequate dietary folate. MDD‐W was generally unassociated with homocysteine. However, there was an interaction between MDD‐W and sex of the infant. Namely, MDD‐W ≥ 3 predicted increased probability of normal homocysteine among mothers with female infants but not male infants.ConclusionsDiets consisting of three or more food groups may protect adequate folate intake for many breastfeeding mothers. More research is needed to establish what level of dietary diversity would protect against hyperhomocysteinemia during breastfeeding and what factors promote or hinder the benefit of diversified diets on maternal folate nutrition.

01 Jun 2024·International Journal of Antimicrobial Agents

The discovery of an anti-Candida xanthone with selective inhibition of Candida albicans GAPDH

Article

Author: Yang, Ming-Hua ; Fang, Zhan-Hong ; Wang, Kai-Bo ; Chen, Xing-Ru ; Zhou, Zhuo-Da ; Kong, Ling-Yi ; Zhang, Chao ; Zhou, Tao

OBJECTIVESThis study aimed to discover novel antifungals targeting Candida albicans glyceraldehyde-3-phosphate dehydrogenase (CaGAPDH), have an insight into inhibitory mode, and provide evidence supporting CaGAPDH as a target for new antifungals.METHODSVirtual screening was utilized to discover inhibitors of CaGAPDH. The inhibitory effect on cellular GAPDH was evaluated by determining the levels of ATP, NAD, NADH, etc., as well as examining GAPDH mRNA and protein expression. The role of GAPDH inhibition in C. albicans was supported by drug affinity responsive target stability and overexpression experiments. The mechanism of CaGAPDH inhibition was elucidated by Michaelis-Menten enzyme kinetics and site-specific mutagenesis based on docking. Chemical synthesis was used to produce an improved candidate. Different sources of GAPDH were used to evaluate inhibitory selectivity across species. In vitro and in vivo antifungal tests, along with anti-biofilm activity, were carried out to evaluate antifungal potential of GAPDH inhibitors.RESULTSA natural xanthone was identified as the first competitive inhibitor of CaGAPDH. It demonstrated in vitro anti-C. albicans potential but also caused hemolysis. XP-W, a synthetic side-chain-optimized xanthone, demonstrated a better safety profile, exhibiting a 50-fold selectivity for CaGAPDH over human GAPDH. XP-W also exhibited potent anti-biofilm activity and displayed broad-spectrum anti-Candida activities in vitro and in vivo, including multi-azole-resistant C. albicans.CONCLUSIONSThese results demonstrate for the first time that CaGAPDH is a valuable target for antifungal drug discovery, and XP-W provides a promising lead.

01 Jun 2024·European Archives of Oto-Rhino-Laryngology

Plus moist HS-W®: a new nasal packing material for the middle meatus in endoscopic sinus surgery

Article

Author: Wakasugi, Ryo ; Sasaki, Takanobu ; Ikeda, Ryo ; Horii, Arata ; Yoshioka, Kuniaki ; Takano, Satoshi ; Kamada, Hisashi ; Matsuyama, Hiroshi ; Tochigi, Kaori ; Takahashi, Nao

AbstractPurposeRemoval of the current calcium alginate packing materials to the middle meatus in endoscopic sinus surgery (ESS) is usually accompanied by discomfort or pain owing to the hard and brittle nature of these materials. Plus moist HS-W® is a new calcium alginate packing material released in 2022 developed to overcome this issue by changing the uronic acid component. We aimed to compare the discomfort/pain during the removal of Plus moist HS-W® with Kaltostat®, as well as their suitability as packing materials in ESS.MethodsKaltostat® and Plus moist HS-W® were used as packing materials in 22 and 21 patients who underwent ESS in 2021 and 2022, respectively. Patients were asked to rate the pain during the packing removal 10 days after ESS using the Numerical Rating Scale (NRS). The ratio of residual packing materials, number of suctions (insertions/extractions of the suction cannula), and time required to remove packing materials were measured. Postoperative complications such as hemorrhage, local infection, lateralization of the middle turbinate, and synechia of the middle meatus were also evaluated.ResultsThe Plus moist HS-W® group exhibited significantly lower NRS pain scores, a lower ratio of residual packing materials, a reduced number of suctions, and a shorter time required to remove the packing. No obvious postoperative complications occurred in both groups except for one suspicious case of a slight infection in the Kaltostat® group.ConclusionCompared with Kaltostat®, Plus moist HS-W®, characterized by better gelatinization than Kaltostat®, benefits patients by minimizing discomfort/pain during removal.Level of evidenceLevel 3.

100 Deals associated with Engineered skin substitute(Lonza Group AG)

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burns	Phase 2	US	Amarantus Bioscience Holdings, Inc.	01 Sep 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Engineered skin substitute(Lonza Group AG)

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation